We interviewed Dr. Renier Brentjens, Medical Oncologist at Memorial Sloan-Kettering Cancer Center, on the role of small studies in advancing the development of cell therapies.
Dr. Brentjens has been quoted in several articles in scientific journals and newspapers, such as Science Translational Medicine, the New York Times and the Wall Street Journal. He is the first author of a study for a treatment which genetically alters a patient's own immune cells to fight various types of acute lymphocytic leukemia (ALL), through a T-cell therapy.
Interview questions include:
- In your opinion, what is the role and real value of small studies in advancing cell therapies' research and development?
- Is the FDA too stringent when evaluating these experimental approaches, or is it just a matter of adapting these small studies to comply with the current framework for biologics?
- Was this recent study experimental to showcase better and faster results when stakeholders in the cell therapy space collaborate? What is missing?
- What are the next steps for this trial/experimental therapy? What challenges do you foresee?
- Where will funding to continue the development of the therapy come from?
- â¦and more!
To see the answers, get a copy of the interview here.
Dr. Brentjens will be speaking at the upcoming Stem Cells & Regenerative Medicine Congress on the topic, âDeploying small studies to uncover new therapy pathways.' Download the brochure for more information.